BRPI0607863B8 - sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo - Google Patents

sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo

Info

Publication number
BRPI0607863B8
BRPI0607863B8 BRPI0607863A BRPI0607863A BRPI0607863B8 BR PI0607863 B8 BRPI0607863 B8 BR PI0607863B8 BR PI0607863 A BRPI0607863 A BR PI0607863A BR PI0607863 A BRPI0607863 A BR PI0607863A BR PI0607863 B8 BRPI0607863 B8 BR PI0607863B8
Authority
BR
Brazil
Prior art keywords
ylcarbonyl
thiazolidine
piperazin
pyrazol
pyrrolidin
Prior art date
Application number
BRPI0607863A
Other languages
English (en)
Inventor
Akahoshi Fumihiko
Sakashita Hiroshi
Ueda Naoko
Tsutsumiuchi Reiko
Uemori Satoru
Kirihara Shinji
Yoshida Tomohiro
Original Assignee
Mitsubishi Pharma Corp
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36916526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607863(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Pharma Corp, Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of BRPI0607863A2 publication Critical patent/BRPI0607863A2/pt
Publication of BRPI0607863B1 publication Critical patent/BRPI0607863B1/pt
Publication of BRPI0607863B8 publication Critical patent/BRPI0607863B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

sal de derivado de prolina, solvato do mesmo e método para produção do mesmo. a presente invenção proporciona 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina (composto i) útil como um inibidor de dipeptidil peptidase-iv, que tem propriedades superiores de estabilidade e higroscopicidade, e um método para produção do mesmo.
BRPI0607863A 2005-02-18 2006-02-17 sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo BRPI0607863B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005041851 2005-02-18
JP2005-041851 2005-02-18
PCT/JP2006/302827 WO2006088129A1 (ja) 2005-02-18 2006-02-17 プロリン誘導体の塩、またはその溶媒和物、及びその製造方法

Publications (3)

Publication Number Publication Date
BRPI0607863A2 BRPI0607863A2 (pt) 2010-06-22
BRPI0607863B1 BRPI0607863B1 (pt) 2020-10-20
BRPI0607863B8 true BRPI0607863B8 (pt) 2021-05-25

Family

ID=36916526

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607863A BRPI0607863B8 (pt) 2005-02-18 2006-02-17 sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo

Country Status (14)

Country Link
US (2) US8003790B2 (pt)
EP (2) EP2602259A3 (pt)
JP (3) JP4208938B2 (pt)
KR (2) KR101352650B1 (pt)
CN (3) CN102372705A (pt)
AU (1) AU2006215041B2 (pt)
BR (1) BRPI0607863B8 (pt)
CA (1) CA2598301C (pt)
EA (1) EA013119B1 (pt)
ES (1) ES2588164T3 (pt)
MX (1) MX2007010054A (pt)
NZ (1) NZ561489A (pt)
TW (1) TWI403511B (pt)
WO (1) WO2006088129A1 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4208938B2 (ja) * 2005-02-18 2009-01-14 田辺三菱製薬株式会社 プロリン誘導体の塩、またはその溶媒和物、及びその製造方法
DE602006017997D1 (de) * 2005-04-26 2010-12-16 Mitsubishi Tanabe Pharma Corp Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel
CN103330939A (zh) 2007-04-03 2013-10-02 田边三菱制药株式会社 二肽基肽酶iv抑制化合物和甜味剂的并用
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
JP5775463B2 (ja) * 2009-12-18 2015-09-09 田辺三菱製薬株式会社 溶出安定性製剤
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP5863789B2 (ja) * 2011-06-01 2016-02-17 田辺三菱製薬株式会社 ピラゾール誘導体の製造方法
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
BR112014003798A2 (pt) 2011-08-19 2017-03-01 Merck Sharp & Dohme método para fabricar um composto, e, composto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9518048B2 (en) 2012-08-31 2016-12-13 Glenmark Pharmaceuticals Limited Process for the preparation of teneligliptin
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
CN104230917B (zh) * 2013-06-24 2017-04-05 南京华威医药科技开发有限公司 一种脯氨酸衍生物盐的水合物及其生产方法
WO2015019238A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one
WO2015019239A1 (en) 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
WO2015063709A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of 1-(3-methyl-1-phenyl-1h-pyrazol-5-yl)piperazine
CN104650065A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种替格列汀化合物
WO2015173779A1 (en) 2014-05-16 2015-11-19 Micro Labs Limited Process for the preparation of teneligliptin and its novel intermediates
CN105294673B (zh) * 2014-06-18 2018-04-13 四川科伦药物研究院有限公司 一种氢溴酸替格列汀的合成方法
JP2019508385A (ja) * 2017-02-03 2019-03-28 グレンマーク・ファーマシューティカルズ・リミテッド テネリグリプチンのシュウ酸塩およびその溶媒和物、中間体、その調製方法およびマーカー
CN108727364A (zh) * 2017-04-18 2018-11-02 乳源东阳光药业有限公司 一种氢溴酸替格列汀无定型及其制备方法
JP2021522332A (ja) * 2018-04-25 2021-08-30 乳源▲東▼▲陽▼光▲薬▼▲業▼有限公司 テネリグリプチン臭化水素酸塩アモルファス及びその調製方法
KR102494848B1 (ko) 2018-10-10 2023-02-02 주식회사 파마코스텍 테네리글립틴 2토실산염 2수화물의 결정형 ⅰ형 및 그 제조방법
KR20200127480A (ko) 2019-05-02 2020-11-11 연성정밀화학(주) 테네리글립틴 에디실산염 결정형 및 이의 제조방법
KR20210121421A (ko) 2020-03-30 2021-10-08 코오롱생명과학 주식회사 테네리글리프틴 2.5브롬화수소산염 무정형의 제조방법
JP2022069426A (ja) * 2020-10-23 2022-05-11 マイラン ラボラトリーズ リミテッド テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US6090786A (en) * 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
EP1254113A1 (en) 2000-01-24 2002-11-06 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
HUP0301622A3 (en) 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
ES2334858T3 (es) * 2000-08-10 2010-03-16 Mitsubishi Tanabe Pharma Corporation Derivados de prolina y uso de los mismos como farmacos.
SK10802003A3 (sk) 2001-02-02 2004-05-04 Takeda Chemical Industries, Ltd. Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
GB0115517D0 (en) 2001-06-25 2001-08-15 Ferring Bv Novel antidiabetic agents
CA2460512A1 (en) * 2001-09-14 2003-03-27 Mitsubishi Pharma Corporation Thiazolidine derivatives and medicinal use thereof
US20040229848A1 (en) * 2003-05-05 2004-11-18 Hans-Ulrich Demuth Glutaminyl based DP IV-inhibitors
AU2003902946A0 (en) * 2003-06-12 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
JP4569802B2 (ja) 2003-07-23 2010-10-27 眞 八藤 ビタミンを主材とするイオン化ミネラル結合型サプリメントの製造方法
JP4208938B2 (ja) * 2005-02-18 2009-01-14 田辺三菱製薬株式会社 プロリン誘導体の塩、またはその溶媒和物、及びその製造方法
DE602006017997D1 (de) * 2005-04-26 2010-12-16 Mitsubishi Tanabe Pharma Corp Prophylaktisches/therapeutisches mittel für abweichungen im fettstoffwechsel
US8754032B2 (en) * 2005-06-03 2014-06-17 Mitsubishi Tanabe Pharma Corporation Concomitant pharmaceutical agents and use thereof

Also Published As

Publication number Publication date
KR20070108247A (ko) 2007-11-08
US20110282058A1 (en) 2011-11-17
KR20130076903A (ko) 2013-07-08
BRPI0607863B1 (pt) 2020-10-20
EP2602259A2 (en) 2013-06-12
CN101119991B (zh) 2012-01-25
CN102372704B (zh) 2014-10-08
JPWO2006088129A1 (ja) 2008-07-03
EP1854795A4 (en) 2009-03-25
KR101352650B1 (ko) 2014-01-16
US20090216016A1 (en) 2009-08-27
CA2598301A1 (en) 2006-08-24
AU2006215041B2 (en) 2012-05-31
CN101119991A (zh) 2008-02-06
US8604198B2 (en) 2013-12-10
JP2013032376A (ja) 2013-02-14
TWI403511B (zh) 2013-08-01
MX2007010054A (es) 2007-09-21
CA2598301C (en) 2013-05-28
EP1854795B1 (en) 2016-06-01
EA200701756A1 (ru) 2008-02-28
CN102372704A (zh) 2012-03-14
NZ561489A (en) 2010-10-29
WO2006088129A1 (ja) 2006-08-24
ES2588164T3 (es) 2016-10-31
JP2008214358A (ja) 2008-09-18
AU2006215041A1 (en) 2006-08-24
BRPI0607863A2 (pt) 2010-06-22
EP2602259A3 (en) 2014-09-10
EP1854795A1 (en) 2007-11-14
JP4208938B2 (ja) 2009-01-14
US8003790B2 (en) 2011-08-23
EA013119B1 (ru) 2010-02-26
TW200640920A (en) 2006-12-01
CN102372705A (zh) 2012-03-14

Similar Documents

Publication Publication Date Title
BRPI0607863B8 (pt) sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
TW200745066A (en) Novel PTP1B inhibitors
BRPI0612072A2 (pt) inibidores da aspartil protease
UY32285A (es) Compuestos heterocíclicos fungicidas
TW200607805A (en) Novel pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
ATE530519T1 (de) Cyclobutylaminderivate
BRPI0817843B8 (pt) inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
TN2009000249A1 (en) Mapk/erk kinase inhibitors
ECSP056240A (es) Derivados de pirido[2,1-a]isoquinolina como inhibidores de dpp-iv
BRPI0919873A2 (pt) composto de pirazol[1,5-a]pirimidina substituídos como inibidores da quinase trk
WO2007079199A3 (en) Substituted bis-amide metalloprotease inhibitors
UY28821A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.
TW200714586A (en) Crystalline forms of a biphenyl compound
MA43288A1 (fr) Procédés de production et formes cristallines d'un inhibiteur mdm2
AR060648A1 (es) Formas cristalinas de un compuesto de dimetilfenilo carbamoil etil piperidina
BRPI0618379A2 (pt) processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
MX2012002752A (es) Compuestos de heteroarilo como inhibidores de cinasa.
MY152283A (en) Polo-like kinase inhibitirs
GEP20104941B (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
BRPI0408888A (pt) processo para a preparação de derivados de 1-n-(fenil)-2-n-(fenil) pirrolidina-1,2-dicarboxamida e derivados de ácido 1-(fenilcarbamoil) pirrolidina-2-carboxìlico como intermediários
BR112012007069A2 (pt) derivado de fenol
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA DA PETICAO NO 020080090454/RJ DE 27/06/2008, O PEDIDO DE ALTERACAO DE NOME POR AUSENCIA DE FUNDAMENTACAO LEGAL.

B25A Requested transfer of rights approved

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

Free format text: TRANSFERIDO POR INCORPORACAO DE: MITSUBISHI PHARMA CORPORATION

B25E Requested change of name of applicant rejected

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2710 DE 13-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.